ClinicalTrials.gg

Program

suvemcitug

Also written as “Sevacizumab”, “BD0801” and “Suvemcitug injection, trifluridine/tipiracil tablets”.

Its studies are mostly in Colorectal Neoplasms · Ovarian Neoplasms, led by Simcere Pharmaceutical Group.

Furthest: phase 3, since May 27, 20216 company-led studies, 1 open or runningNext primary completion: Jan 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Simcere Pharmaceutical Group61 open or runningphase 3since May 27, 2021Apr 26, 2013Jan 2028phase 3 · NCT07361003

Also a collaborator on its studies: shanghai-xianxiang-medical-technology-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 26, 2013First study: phase 1 study in Advanced Solid TumorsFirst studyNCT01847118 · 31 enrolled · China
  2. May 19, 2015Phase 1 study in Colorectal NeoplasmsNCT02453464 · 36 enrolled · China
  3. Nov 25, 2018Phase 1 study in Ovarian NeoplasmsNCT03763123 · 48 enrolled · China
  4. May 27, 2021Phase 3 study in Ovarian NeoplasmsNCT04908787 · 421 enrolled · China
  5. Nov 15, 2021Phase 2 study in Advanced Solid TumorNCT05148195 · 86 enrolled · China
  6. Sep 30, 2025Phase 3 study in Colorectal NeoplasmsNCT07361003 · 464 planned · China

Ahead

  1. Jan 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT07361003

TargetBeta

VEGFA →read by rule
“A monoclonal antibody directed against the human vascular endothelial growth factor (VEGF), ”NCIt, by rule

Other programs on VEGFA

ProgramCompanyFurthest phaseStudies
BevacizumabruleHoffmann-La Rochephase 4250
RanibizumabruleNovartisphase 4108
afliberceptruleRegeneron Pharmaceuticalsphase 489
faricimabruleHoffmann-La Rochephase 417
ivonescimabruleAkesophase 348
pumitamigBioNTechphase 334
tivunatamigPfizerphase 315
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
surabgene lomparvovecAbbViephase 32
ABBV-1480RemeGenphase 32
HLX37Fosun Pharmaphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07361003Colorectal Neoplasms · China3RecruitingJan 2028464
NCT05148195Advanced Solid Tumor · China2TerminatedJul 26, 202386
NCT04908787Ovarian Neoplasms · China3CompletedDec 8, 2023421
NCT03763123Ovarian Neoplasms · China1UNKNOWNDec 31, 201948
NCT02453464Colorectal Neoplasms · China1UNKNOWNDec 201636
NCT01847118Advanced Solid Tumors · China1UNKNOWNNov 201531

How it is read

Names in the registry

  • “Sevacizumab”, 3 entries
  • “BD0801”, 2 entries
  • “Suvemcitug injection, trifluridine/tipiracil tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.